Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.4800
- TODAY'S CHANGE (%)-0.0100 (-0.2865%)
- Bid / Lots3.4500/ 15
- Ask / Lots3.5000/ 1
- Open / Previous Close3.4900 / 3.4900
- Day Range
- 52 Week Range
- Volume867,270
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 10259 | 3.45 |
| 09:34 ET | 9300 | 3.44 |
| 09:36 ET | 6397 | 3.4 |
| 09:38 ET | 10350 | 3.42 |
| 09:39 ET | 2672 | 3.46 |
| 09:41 ET | 450 | 3.445 |
| 09:43 ET | 400 | 3.465 |
| 09:45 ET | 200 | 3.465 |
| 09:48 ET | 300 | 3.48 |
| 09:50 ET | 16425 | 3.5 |
| 09:52 ET | 1888 | 3.48 |
| 09:54 ET | 500 | 3.49 |
| 09:56 ET | 12900 | 3.53 |
| 09:57 ET | 6900 | 3.51 |
| 09:59 ET | 23414 | 3.505 |
| 10:01 ET | 500 | 3.52 |
| 10:03 ET | 1630 | 3.525 |
| 10:06 ET | 3550 | 3.52 |
| 10:08 ET | 600 | 3.515 |
| 10:10 ET | 1600 | 3.485 |
| 10:12 ET | 1800 | 3.5 |
| 10:14 ET | 1750 | 3.505 |
| 10:15 ET | 3762 | 3.525 |
| 10:17 ET | 2395 | 3.505 |
| 10:19 ET | 2500 | 3.475 |
| 10:21 ET | 1300 | 3.465 |
| 10:24 ET | 10110 | 3.445 |
| 10:26 ET | 6811 | 3.455 |
| 10:28 ET | 1100 | 3.465 |
| 10:30 ET | 1000 | 3.465 |
| 10:32 ET | 1100 | 3.465 |
| 10:33 ET | 1840 | 3.475 |
| 10:35 ET | 2808 | 3.475 |
| 10:37 ET | 700 | 3.475 |
| 10:39 ET | 500 | 3.47 |
| 10:42 ET | 1600 | 3.48 |
| 10:44 ET | 350 | 3.475 |
| 10:46 ET | 600 | 3.485 |
| 10:48 ET | 1696 | 3.49 |
| 10:50 ET | 600 | 3.485 |
| 10:51 ET | 400 | 3.485 |
| 10:53 ET | 11900 | 3.485 |
| 10:55 ET | 1300 | 3.475 |
| 10:57 ET | 4430 | 3.475 |
| 11:00 ET | 1500 | 3.475 |
| 11:02 ET | 1000 | 3.47 |
| 11:04 ET | 800 | 3.475 |
| 11:06 ET | 4285 | 3.495 |
| 11:08 ET | 3400 | 3.475 |
| 11:09 ET | 7000 | 3.475 |
| 11:11 ET | 1358 | 3.475 |
| 11:13 ET | 800 | 3.475 |
| 11:15 ET | 200 | 3.475 |
| 11:18 ET | 650 | 3.474 |
| 11:20 ET | 1602 | 3.49 |
| 11:22 ET | 356 | 3.4899 |
| 11:24 ET | 1800 | 3.485 |
| 11:26 ET | 1300 | 3.485 |
| 11:27 ET | 1200 | 3.49 |
| 11:29 ET | 1511 | 3.475 |
| 11:31 ET | 9151 | 3.465 |
| 11:33 ET | 2325 | 3.475 |
| 11:36 ET | 500 | 3.475 |
| 11:38 ET | 1100 | 3.475 |
| 11:40 ET | 600 | 3.475 |
| 11:42 ET | 484 | 3.475 |
| 11:44 ET | 1000 | 3.475 |
| 11:45 ET | 16933 | 3.45 |
| 11:47 ET | 400 | 3.45 |
| 11:49 ET | 1100 | 3.455 |
| 11:51 ET | 3300 | 3.465 |
| 11:54 ET | 1100 | 3.465 |
| 11:56 ET | 900 | 3.465 |
| 11:58 ET | 847 | 3.46 |
| 12:00 ET | 4677 | 3.455 |
| 12:02 ET | 300 | 3.455 |
| 12:03 ET | 1000 | 3.455 |
| 12:05 ET | 2568 | 3.46 |
| 12:09 ET | 3214 | 3.465 |
| 12:18 ET | 300 | 3.465 |
| 12:20 ET | 2293 | 3.475 |
| 12:21 ET | 460 | 3.48 |
| 12:23 ET | 830 | 3.475 |
| 12:25 ET | 1400 | 3.475 |
| 12:27 ET | 800 | 3.47 |
| 12:30 ET | 200 | 3.475 |
| 12:32 ET | 100 | 3.475 |
| 12:34 ET | 600 | 3.475 |
| 12:36 ET | 500 | 3.475 |
| 12:38 ET | 1557 | 3.49 |
| 12:39 ET | 3039 | 3.485 |
| 12:41 ET | 4100 | 3.475 |
| 12:43 ET | 300 | 3.475 |
| 12:45 ET | 5250 | 3.475 |
| 12:48 ET | 4016 | 3.475 |
| 12:50 ET | 9361 | 3.475 |
| 12:52 ET | 2340 | 3.47 |
| 12:54 ET | 2700 | 3.47 |
| 12:56 ET | 2600 | 3.475 |
| 12:57 ET | 700 | 3.475 |
| 12:59 ET | 4500 | 3.465 |
| 01:01 ET | 6817 | 3.475 |
| 01:03 ET | 2400 | 3.475 |
| 01:06 ET | 3000 | 3.475 |
| 01:08 ET | 400 | 3.475 |
| 01:10 ET | 4600 | 3.45 |
| 01:12 ET | 8588 | 3.445 |
| 01:14 ET | 200 | 3.445 |
| 01:15 ET | 2600 | 3.445 |
| 01:17 ET | 900 | 3.445 |
| 01:19 ET | 700 | 3.445 |
| 01:21 ET | 400 | 3.445 |
| 01:24 ET | 2756 | 3.445 |
| 01:26 ET | 400 | 3.445 |
| 01:28 ET | 1500 | 3.445 |
| 01:30 ET | 3457 | 3.445 |
| 01:32 ET | 400 | 3.445 |
| 01:33 ET | 600 | 3.445 |
| 01:35 ET | 500 | 3.445 |
| 01:37 ET | 5054 | 3.45 |
| 01:39 ET | 400 | 3.445 |
| 01:42 ET | 1513 | 3.45 |
| 01:44 ET | 950 | 3.45 |
| 01:46 ET | 800 | 3.45 |
| 01:48 ET | 4648 | 3.453 |
| 01:50 ET | 4465 | 3.455 |
| 01:51 ET | 192873 | 3.4599 |
| 01:53 ET | 6042 | 3.43 |
| 01:55 ET | 12538 | 3.41 |
| 01:57 ET | 11301 | 3.425 |
| 02:02 ET | 6635 | 3.4145 |
| 02:04 ET | 600 | 3.415 |
| 02:06 ET | 3376 | 3.425 |
| 02:08 ET | 3641 | 3.435 |
| 02:09 ET | 100 | 3.43 |
| 02:11 ET | 300 | 3.44 |
| 02:13 ET | 1948 | 3.435 |
| 02:15 ET | 305 | 3.435 |
| 02:18 ET | 2456 | 3.445 |
| 02:22 ET | 4074 | 3.46 |
| 02:24 ET | 525 | 3.465 |
| 02:26 ET | 4100 | 3.465 |
| 02:27 ET | 4164 | 3.46 |
| 02:29 ET | 1964 | 3.475 |
| 02:33 ET | 1474 | 3.48 |
| 02:38 ET | 100 | 3.475 |
| 02:40 ET | 200 | 3.475 |
| 02:42 ET | 800 | 3.475 |
| 02:44 ET | 3560 | 3.48 |
| 02:45 ET | 500 | 3.485 |
| 02:47 ET | 400 | 3.485 |
| 02:49 ET | 2102 | 3.5 |
| 02:51 ET | 2495 | 3.5 |
| 02:54 ET | 2327 | 3.5 |
| 02:56 ET | 1394 | 3.5 |
| 02:58 ET | 1229 | 3.5 |
| 03:00 ET | 300 | 3.5 |
| 03:02 ET | 1300 | 3.5 |
| 03:03 ET | 1100 | 3.5 |
| 03:05 ET | 2279 | 3.4975 |
| 03:07 ET | 10879 | 3.49 |
| 03:09 ET | 200 | 3.495 |
| 03:12 ET | 300 | 3.495 |
| 03:14 ET | 289 | 3.49 |
| 03:16 ET | 2340 | 3.49 |
| 03:18 ET | 400 | 3.495 |
| 03:20 ET | 300 | 3.495 |
| 03:21 ET | 800 | 3.495 |
| 03:23 ET | 1800 | 3.495 |
| 03:25 ET | 11859 | 3.5 |
| 03:27 ET | 700 | 3.495 |
| 03:30 ET | 500 | 3.495 |
| 03:32 ET | 2029 | 3.495 |
| 03:34 ET | 300 | 3.495 |
| 03:36 ET | 11431 | 3.47 |
| 03:38 ET | 6790 | 3.475 |
| 03:39 ET | 3600 | 3.47 |
| 03:41 ET | 1100 | 3.475 |
| 03:43 ET | 3397 | 3.47 |
| 03:45 ET | 3100 | 3.47 |
| 03:48 ET | 6400 | 3.475 |
| 03:50 ET | 3200 | 3.475 |
| 03:52 ET | 3100 | 3.475 |
| 03:54 ET | 6784 | 3.475 |
| 03:56 ET | 6647 | 3.47 |
| 03:57 ET | 15141 | 3.475 |
| 03:59 ET | 17586 | 3.48 |
Jun 20, 2024
DJ Mereo BioPharma Group Is Maintained at Outperform by Leerink Partners, from 8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 14, 2024
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market, from 7:50AM ET on Friday Jun 14, 2024 by Dow Jones
7:50AM ET on Friday Jun 14, 2024 by Dow JonesPress Release: Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market, from 7:50AM ET on Friday Jun 14, 2024 by Dow Jones
7:50AM ET on Friday Jun 14, 2024 by Dow Jones
Jun 13, 2024
DJ Mereo BioPharma Group Initiated at Outperform by Baird, from 5:27AM ET on Thursday Jun 13, 2024 by Dow Jones
5:27AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 12:25PM ET on Wednesday Jun 12, 2024 by Dow Jones
12:25PM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 533.3M | -11.1x | --- |
AnaptysBio Inc | 651.5M | -4.0x | --- |
SS Innovations International Inc | 683.0M | -32.1x | --- |
Immunome Inc | 721.4M | -2.2x | --- |
Stoke Therapeutics Inc | 727.1M | -5.5x | --- |
Dianthus Therapeutics Inc | 695.3M | -7.8x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $533.3M |
|---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-0.31 |
Book Value | $0.44 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 53.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
